scholarly journals Effect of treatment and mammography detection on breast cancer survival over time: 1990-2007

Cancer ◽  
2015 ◽  
Vol 121 (15) ◽  
pp. 2553-2561 ◽  
Author(s):  
Henry G. Kaplan ◽  
Judith A. Malmgren ◽  
Mary K. Atwood ◽  
Gregory S. Calip
2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 6000-6000 ◽  
Author(s):  
Jeffrey H. Silber ◽  
Paul R. Rosenbaum ◽  
Amy Sanders Clark ◽  
Min Wang ◽  
Yun Teng ◽  
...  

6000 Background: Reducing racial disparities in breast cancer survival has been a federal priority since the early 1990’s. We present a new method to assess disparities using sequential multivariate matching. We ask if racial disparities have increased or decreased over time and if so, what were potential reasons for such changes. Methods: We studied all women over 65 years of age in the Medicare fee for service system diagnosed with breast cancer between 1991 and 2005 who were treated in one of 12 SEER sites (the sites in SEER since 1991). There were 5,251 black patients (74% early stage (I-III), 9% late stage (IV) and 17% missing stage) and 72,695 white patients (81% early stage, 5% late stage and 14% missing stage). All black cases represented the focal group for all matches. Using multivariate matching and the propensity score, white controls were matched to blacks in steps: (1) White controls matched to black cases on age and year of diagnosis; (2) Age, year of diagnosis, and stage; (3): Age, year, stage, estrogen receptor status, grade, and 30 comorbidities. We then compare 5-year survival in the Pre and Post-Taxane periods (1991-1998, 1999-2005). Results: When whites were matched to blacks on age and diagnosis year, 5-year Kaplan-Meier survival was 69.2% vs. 56.7%, P < 0.0001. Matching additionally on stage, differences = 64.1% vs. 56.7%, P < 0.0001; Matching further on tumor characteristics and 30 comorbidities, the disparity reduced to 61.6% vs. 56.7%, P < 0.0001. Comparing trends over time, white-black differences in survival matched for age and year were 67.6% vs. 55.2% (P < 0.0001) in the pre-Taxane era (difference = 12.4%) and 71.2% vs. 58.7% (P < 0.0001) in the post Taxane era (difference = 12.5%); age and year matched paired racial differences were not different across eras (P = 0.389). Conclusions: While there may have been some improvements in overall survival, racial disparities in breast cancer survival have not improved, despite important policy initiatives and treatment advances. Adjusting for presentation at diagnosis does reduce differences in survival, but even these differences remain large and significant, suggesting that differences in both presentation and treatment given presentation are contributing to this disparity.


2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 1589-1589
Author(s):  
Margaret Quinn Rosenzweig ◽  
Su Yon Jung ◽  
Adam Brufsky

1589 Background: Recent evidence suggests that survival in metastatic breast cancer is slowly improving associated with the use of better adjuvant and metastatic chemotherapeutic and targeted agents. Patient and clinical factors such as age, estrogen status, non-white race, Her 2 status, disease free interval and sites of metastatic breast cancer involvement indicate worse clinical outcome after recurrence. This analysis focused on the influence of these factors on metastatic breast cancer survival over time. Methods: Subjects were women with metastatic breast cancer from one large urban practice, of the University of Pittsburgh Cancer Institute Breast Cancer Program followed from 1999 through December, 2008. Patients were dichotomized into two time categories: A) 1999 through 2004 and B) 2005 through 2008. Outliers of long term survivors (n =72) with survival extending beyond 6 years were excluded. Log rank tests were conducted for assessing the relationship between prognostic factors and survival. Results: Cohorts included patients diagnosed with metastatic breast cancer in 1999 through 2004, (n=284) and 2005 through 2008, (n=332). They were followed up to December, 2011. Median survival improved over time (p=0.053). Estrogen negativity remained significant for worse survival across both time periods (p<0.0001). Age, presence of brain metastasis and Her 2 status were not significant for influence on survival at either time interval. Shorter disease free interval (p= 0.02), higher number of metastatic sites (p=.001) and presence of visceral metastasis at diagnosis (p=0.003) became significant for worse survival in the 2005-2008 intervals but had not been in the earlier time period. African American race was highly significant (<0.001) for worse survival in 1999-2004 but lost significance in 2005 through 2008 with dramatic survival increase (median survival - 12.5 months to 35 months). Conclusions: It is important for clinicians to clarify the prognostic features associated with worse outcomes in metastatic breast cancer. With newly emergent therapies and sensitivity toward specific patient factors these features evolve over time.


Sign in / Sign up

Export Citation Format

Share Document